Non-alcoholic Fatty Liver Disease: Clinical Trials

835 completed, 313 unknown, 163 recruiting, 94 terminated. 549 Not applicable, 346 Phase 2, 177 Phase 1, 88 Phase 3, 80 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	549	Completed 288, Unknown 130, Recruiting 53, Active not recruiting 24, Terminated 17, Not yet recruiting 15, Withdrawn 13, Enrolling by invitation 9
Phase 2	346	Completed 217, Terminated 46, Unknown 27, Recruiting 24, Active not recruiting 16, Withdrawn 10, Not yet recruiting 6
Phase 1	177	Completed 129, Unknown 13, Terminated 12, Recruiting 11, Withdrawn 7, Active not recruiting 3, Not yet recruiting 2
Phase 3	88	Completed 43, Unknown 13, Recruiting 9, Terminated 8, Active not recruiting 6, Withdrawn 4, Not yet recruiting 3, Enrolling by invitation 1, Suspended 1
Phase 4	80	Completed 45, Unknown 17, Terminated 5, Active not recruiting 4, Recruiting 4, Withdrawn 3, Not yet recruiting 2
Early Phase 1	15	Completed 9, Active not recruiting 2, Not yet recruiting 2, Unknown 1, Withdrawn 1

Follow Non-alcoholic Fatty Liver Disease: new trials by email Literature Review of Non-alcoholic Fatty Liver Disease trials Research Report on Non-alcoholic Fatty Liver Disease

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Liver Steatosis in Pediatric CD Patients Gluten-free diet - Celiac Disease in Children, Non-Alcoholic Fatty Liver Disease		Recruiting	University of Palermo	91	2027-11-01	2026-05-01
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease Empagliflozin 10 MG, Placebo Oral Tablet - Non-Alcoholic Fatty Liver Disease, NAFLD	Phase 2	Not yet recruiting	Justin Ryder	40	2027-05-01	2026-01-20
Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia	Phase 1	Not yet recruiting	Columbia University	36	2027-01-01	2026-02-06
RE and Probiotics in MAFLD/NAFLD physical exercise programme, probiotics supplementation, Placebo - NASH, NAFLD	Not applicable	Not yet recruiting	Nicolaus Copernicus University	180	2026-11-10	2026-10-21
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD	Phase 3	Not yet recruiting	Regeneron Pharmaceuticals	1500	2026-11-06	2026-10-02
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine ECC0509, Metformin, Caffeine - Steatohepatitis, Nonalcoholic, Osteo Arthritis	Phase 1	Not yet recruiting	Eccogene	40	2026-11-01	2026-10-14
Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections		Not yet recruiting	Assiut University	250	2026-11-01	2026-10-06
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks No intervention; observational assessment only - Obesity & Overweight, Diabetes Mellitus, Type 2		Not yet recruiting	Shanxi Bethune Hospital	25974	2026-11-01	2026-10-21
Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness Wearable Patch-Type Ultrasound Probe, Transient Elastography (FibroScan) - Liver Fibrosis, Liver Cirrhosis		Not yet recruiting	Second Affiliated Hospital of Xi'an Jiaotong University	150	2026-10-01	2026-07-21
Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease		Not yet recruiting	Assiut University	120	2026-10-01	2026-09-18
Hypothyroidism and Liver Fibrosis Severity in MASLD Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism		Not yet recruiting	Assiut University	85	2026-10-01	2026-08-28
The Effects of 5-methyltetrahydrofolate Supplementation in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease 5-methyltetrahydrofolate (5-MTHF), placebo group - Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)	Not applicable	Not yet recruiting	Tabriz University of Medical Sciences	44	2026-09-30	2026-07-31
Nutritional Indices and Inflammatory Markers in MASLD Liver Fibrosis, Malnutrition		Not yet recruiting	Assiut University	180	2026-09-20	2026-09-22
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide Mazdutide(Dual GLP-1R/GCGR Agonist), Semaglutide (1 Mg Dose) - Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus	Not applicable	Not yet recruiting	Tianjin Medical University	72	2026-09-15	2026-07-20
Misocholic Tablets for Non-Viral Elevated Liver Enzymes Misocholic Tab, Placebo, Silymarin (Silybum marianum) - Alcohol-Related Liver Disease, Drug-Induced Liver Injury	Phase 3	Not yet recruiting	Hanoi Medical University	60	2026-09-15	2026-09-22
Duodenal pulsENDO as an Early Treatment for Type 2 DM pulsENDO treatment - Diabete Mellitus, T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)	Not applicable	Recruiting	Chinese University of Hong Kong	40	2026-09-01	2026-09-15
Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis Mazdutide injection - Cirrhosis, Portal Hypertension	Not applicable	Not yet recruiting	The Second Affiliated Hospital of Chongqing Medical University	50	2026-09-01	2026-09-01
Linzhi Jianghuang Fufang Huoxue Anshen Capsule for Non-alcoholic Fatty Liver Linzhi Jianghuang Fufang Huoxue Anshen Capsule (LJF), Placebo - Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)	Phase 2	Not yet recruiting	Hong Kong Baptist University	180	2026-09-01	2026-06-09
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP) Digital health interventions - Type 2 Diabetes, Coronary Heart Disease	Not applicable	Recruiting	University of Eastern Finland	1400	2026-09-01	2026-10-06
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia DR10624 Injection, Matching Placebo for DR10624 - Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia	Phase 3	Not yet recruiting	Zhejiang Doer Biologics Co., Ltd.	480	2026-08-17	2026-07-10

Showing 20 of 1596. Sign in to see all of them.

Narrower conditions

Fatty Liver (262)  ·  Obesity (228)  ·  Diabetes Mellitus, Type 2 (137)  ·  Liver Cirrhosis (133)  ·  Liver Diseases (93)  ·  Metabolic Syndrome (92)  ·  Fibrosis (90)  ·  Insulin Resistance (90)  ·  Diabetes Mellitus (73)  ·  Overweight (47)  ·  Cardiovascular Diseases (35)  ·  Dyslipidemias (33)  ·  Motor Activity (33)  ·  Weight Loss (30)

Broader conditions

Digestive System Diseases (1578)  ·  Liver Diseases (1503)  ·  Fatty Liver (1334)  ·  Nutritional and Metabolic Diseases (520)  ·  Pathological Conditions, Signs and Symptoms (509)  ·  Metabolic Diseases (355)  ·  Glucose Metabolism Disorders (322)  ·  Signs and Symptoms (297)  ·  Body Weight (282)  ·  Nutrition Disorders (281)  ·  Overnutrition (278)  ·  Pathologic Processes (266)  ·  Overweight (231)  ·  Endocrine System Diseases (222)  ·  Hyperinsulinism (159)

Interventions

Exercise (40)  ·  Metformin (29)  ·  Pioglitazone (23)  ·  Vitamin E (23)  ·  semaglutide (21)  ·  Bariatric Surgery (20)  ·  empagliflozin (20)  ·  Diet (19)  ·  Diet, Mediterranean (17)  ·  Blood Specimen Collection (12)  ·  Diet, Fat-Restricted (12)  ·  Probiotics (11)  ·  Diet Therapy (10)  ·  Hematologic Tests (10)  ·  Magnetic Resonance Imaging (10)

Sponsors

Assiut University (23)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (20)  ·  Gilead Sciences (16)  ·  Massachusetts General Hospital (16)  ·  Cairo University (15)  ·  Pfizer (15)  ·  AstraZeneca (14)  ·  University of California, San Diego (14)  ·  Columbia University (13)  ·  Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis (12)  ·  Maastricht University Medical Center (12)  ·  Novo Nordisk A/S (12)  ·  Chinese University of Hong Kong (11)  ·  Institute of Liver and Biliary Sciences, India (11)  ·  Tanta University (11)

Countries

United States (542)  ·  China (141)  ·  United Kingdom (120)  ·  France (103)  ·  Italy (97)  ·  Canada (91)  ·  Germany (89)  ·  Spain (78)  ·  Egypt (68)  ·  Puerto Rico (65)  ·  Israel (62)  ·  South Korea (61)  ·  Belgium (57)  ·  Australia (54)  ·  Denmark (47)

Top investigators

Stephen Harrison, MD (7)  ·  Joshua R Cook, MD, PhD (6)  ·  Ali MA Ismail, lecturer (4)  ·  Edward Doo, MD (4)  ·  Kavita Juneja, MD (4)

Results publications

PMID 36318027, PMID 40434633, PMID 33307033, PMID 36750244, PMID 37786277, PMID 40568349, PMID 26707365, PMID 30639779, PMID 33454241, PMID 39326675, PMID 17081293, PMID 18086506, PMID 18820647, PMID 19827166, PMID 20427778, PMID 21520200, PMID 21618575, PMID 22338037, PMID 22431131, PMID 23396737, PMID 24042449, PMID 24187469, PMID 24360972, PMID 24740208, PMID 24743428, PMID 25040896, PMID 26602219, PMID 28039099, PMID 28346567, PMID 28545937, PMID 29990488, PMID 30221912, PMID 30779990, PMID 31271665, PMID 32027858, PMID 32147362, PMID 32360804, PMID 33210751, PMID 33657443, PMID 33666272, PMID 33860116, PMID 33993853, PMID 34635855, PMID 34670043, PMID 35291351, PMID 35820779, PMID 36727674, PMID 36930148, PMID 37287520, PMID 37662597

NIH funding

2019 (13), 2016 (12), 2018 (9), 2017 (6), 2023 (6), U01DK061730 (6), U01DK061728 (5), U01DK061732 (4), U01DK061737 (4), 2025 (3), K12DK133995 (3), P30DK063608 (3), R01HD040787 (3), U01DK061713 (3), U01DK061718 (3)